Squamous cell carcinoma of head and neck
Not recruitingStudy of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease
Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease
- Disease:Squamous cell carcinoma of head and neck
- Substances:PembrolizumabPetosemtamab
Poland- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
- Sponsor:Genmab A/S










